title: Kinetic studies with the non-nucleoside human immunodeficiency virus type-1 reverse transcriptase inhibitor U-90152E.
abstract: The bisheteroarylpiperazine U-90152E is a potent inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) and possesses excellent anti-HIV activity in HIV-1-infected lymphocytes grown in tissue culture. The compound inhibits both the RNA- and DNA-directed DNA polymerase functions of HIV-1 RT. Kinetic studies were carried out to elucidate the mechanism of RT inhibition by U-90152E. Michaelis-Menten kinetics, which are based on the establishment of a rapid equilibrium between the enzyme and its substrates, proved inadequate for the analysis of the experimental data. The data were thus analyzed using Briggs-Haldane kinetics, assuming that the reaction is ordered in that the template:primer binds to the enzyme first, followed by the addition of dNTP and that the polymerase is a processive enzyme. Based on these assumptions, a velocity equation was derived, which allows the calculation of all the essential forward and backward rate constants for the reactions occurring between the enzyme, its substrates and the inhibitor. The results obtained indicate that U-90152E acts exclusively as a mixed inhibitor with respect to the template: primer and dNTP binding sites for both the RNA- and DNA-directed DNA polymerase domains of the enzyme. The inhibitor shows a significantly higher binding affinity for the enzyme-substrate complexes than for the free enzyme and consequently does not directly impair the functions of the substrate binding sites. Therefore, U-90152E appears to impair an event occurring after the formation of the enzyme-substrate complexes, which involves either inhibition of the phosphoester bond formation or translocation of the enzyme relative to its template:primer following the formation of the ester bond.
authors.affiliation: Upjohn Company, Kalamazoo, MI 49001.
authors.forename: I W
authors.initials: IW
authors.lastname: Althaus
authors.forename: J J
authors.initials: JJ
authors.lastname: Chou
authors.forename: A J
authors.initials: AJ
authors.lastname: Gonzales
authors.forename: M R
authors.initials: MR
authors.lastname: Deibel
authors.forename: K C
authors.initials: KC
authors.lastname: Chou
authors.forename: F J
authors.initials: FJ
authors.lastname: Kezdy
authors.forename: D L
authors.initials: DL
authors.lastname: Romero
authors.forename: R C
authors.initials: RC
authors.lastname: Thomas
authors.forename: P A
authors.initials: PA
authors.lastname: Aristoff
authors.forename: W G
authors.initials: WG
authors.lastname: Tarpley
mesh_terms: D000998:Antiviral Agents / Q000494:pharmacology*; D020008:Delavirdine; D054303:HIV Reverse Transcriptase; D007211:Indoles / Q000494:pharmacology*; D007700:Kinetics; D008433:Mathematics; D010879:Piperazines / Q000494:pharmacology*; D012194:RNA-Directed DNA Polymerase / Q000737:chemistry; D011994:Recombinant Proteins / Q000037:antagonists & inhibitors; D018894:Reverse Transcriptase Inhibitors; D013698:Templates, Genetic
chemical_list: D000998:Antiviral Agents; D007211:Indoles; D010879:Piperazines; D011994:Recombinant Proteins; D018894:Reverse Transcriptase Inhibitors; D020008:Delavirdine; D054303:HIV Reverse Transcriptase; D012194:RNA-Directed DNA Polymerase